local_hospital

Central Finland Hospital District Central Finland Hospital Nova

Address
lock Available on a paid plan

Neoplasm Research at Central Finland Hospital District Central Finland Hospital Nova

This site supports clinical research in cancer care, with studies focused on breast cancer, prostate cancer, and colorectal cancer. The trials aim to improve treatment effectiveness, slow disease progression, and better understand outcomes for people with advanced or high-risk disease.

  • Testing new approaches to help delay progression in prostate cancer
  • Evaluating added treatment options for early-stage, high-risk breast cancer
  • Studying resectability, postoperative outcomes, and survival in metastatic colorectal cancer

This work reflects a strong focus on both treatment improvement and real-world cancer outcomes in Jyvaskyla.

Emergency and Acute Care Diagnostics

Clinical trials here also examine diagnostic techniques for urgent conditions, especially in patients with acute abdomen and reduced kidney function. The research is designed to improve the safety and accuracy of imaging choices in emergency care.

  • Comparing imaging strategies to improve diagnosis in acute abdominal pain
  • Assessing safer diagnostic options for patients with impaired renal function
  • Supporting better decision-making in urgent gastrointestinal evaluation

The emphasis is on improving diagnostic quality while reducing risk for vulnerable patients.

Surgical and Thrombosis Prevention Studies

The site conducts research in health care quality and therapeutics related to surgery, with trials addressing venous thromboembolism prevention. These studies look at how to balance protection from clots with bleeding risk in patients undergoing surgery.

  • Evaluating clot-prevention strategies in surgical patients
  • Studying the benefits and risks of anticoagulant use alongside standard care
  • Improving treatment decisions for patients at uncertain risk of VTE

This research supports safer perioperative care and more individualized prevention strategies.

Digestive System and Appendicitis Research

Another key area is digestive system disease, especially uncomplicated acute appendicitis. The trials aim to compare treatment approaches and strengthen evidence for effective, less invasive care.

  • Comparing antibiotic-based treatment strategies for acute appendicitis
  • Assessing which approach best supports recovery in appendiceal inflammation
  • Improving treatment choices for patients with confirmed appendicitis

This line of research helps clarify how to manage common emergency abdominal conditions more effectively.

Nervous System and Pediatric Prevention Studies

The trial portfolio includes work in nervous system diseases, with a focus on preventing infantile spasms in high-risk infants. These studies explore early intervention for children with conditions that increase the chance of severe seizure disorders.

  • Investigating prevention of infantile spasm syndrome in high-risk infants
  • Studying early treatment for children with tuberous sclerosis or major brain injury
  • Supporting better outcomes in pediatric neurology through preventive care

The goal is to reduce the risk of serious neurological complications during infancy.

Musculoskeletal and Connective Tissue Research

Research at Central Finland Hospital Nova also covers musculoskeletal and skin and connective tissue conditions, particularly Dupuytren's contracture. The studies compare treatment strategies to determine which options work best and offer good value for patients.

  • Comparing treatment approaches for Dupuytren's contracture
  • Evaluating effectiveness and long-term outcomes in hand contracture care
  • Supporting better treatment selection for connective tissue disorders

This research helps refine care for a condition that can limit hand function and daily activity.

Critical Care Research

The site participates in intensive care studies involving adults admitted with acute critical illness. These trials examine commonly used treatments to better understand which approaches improve outcomes in the ICU.

  • Assessing treatment strategies for adults newly admitted to the intensive care unit
  • Studying interventions used in urgent, high-acuity critical care
  • Improving evidence for everyday decision-making in intensive care medicine

The focus is on practical evidence that can support better care for seriously ill patients.

Site Overview

assignment
16
connected trials
corporate_fare
10
sponsors
science
29
IMPs

Activity Indicator

Last 6 months

1
Trials started
New activity detected vs previous period.
0
Trials started 6–12 months ago
16
Total trials linked
Highly Active
trending_upGrowing+100%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 11 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
12
Sponsors (total)
10
Active sponsors
7

Sponsor Network

Top 7 by active trials.

lock +6 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 107 other sites in Finland

description
Trial volume
16
Outperforms 87% of sites
public
Therapeutic diversity
11areas
Outperforms 94% of sites
groups
Sponsor diversity
10sponsors
Outperforms 85% of sites

Therapeutic Area Benchmark — Finland

Select a therapeutic area to compare against other sites in Finland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Finland

Market Share

Country: Finland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Central Finland Hospital District Central Finland Hospital Nova

lock Showing 1 of 16 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020

IMP list

lock Showing 1 of 29 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Apixaban2Unknown2024-05-312024-05-31

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.